Flibanzerin
etil)-1,3-dihidro-2H-benzimidazol-2-on
| (IUPAC) ime | |
|---|---|
| 1-(24-[3-(trifluorometil)fenil]piperazin-1-il | |
| Klinički podaci | |
| Identifikatori | |
| ATC kod | ? |
| Hemijski podaci | |
| Formula | ? |
| Farmakoinformacioni podaci | |
| Trudnoća | ? |
| Pravni status | |
| image = Flibanserin-structural.svg | width = | image2 = | width2 =
| tradename = | pregnancy_category = | legal_status = Nije kontrolisan | routes_of_administration = Oralno
| bioavailability = | metabolism = | elimination_half-life = | excretion =
| CAS_number_Ref = 
| CAS_number = 167933-07-5
| ATC_prefix = none
| ATC_suffix =
| PubChem = 6918248
| IUPHAR_ligand =
| ChemSpiderID_Ref =
| ChemSpiderID = 5293454
| UNII_Ref =
| UNII = 37JK4STR6Z
| KEGG_Ref =
| KEGG = D02577
| ChEMBL_Ref =
| ChEMBL = 231068
| DrugBank_Ref =
| DrugBank =
| C=20 | H=21 | F=3 | N=4 | O=1
| molecular_weight = 390,40 g/mol
| smiles = FC(F)(F)c4cc(N3CCN(CCN2c1ccccc1NC2=O)CC3)ccc4
| InChI = 1/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
| InChIKey = PPRRDFIXUUSXRA-UHFFFAOYAA
| StdInChI_Ref =
| StdInChI = 1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
| StdInChIKey_Ref =
| StdInChIKey = PPRRDFIXUUSXRA-UHFFFAOYSA-N
}}
Flibanserin (BIMT-17, Girosa) je lek koji je razvila kompanija Beringer Ingelhajm kao nehormonski tretman za žene pre menopoze sa poremećajem hipoaktivne seksualne želje.[1][2] Razvoj je prekinut oktobra 2010, nakon što je FDA objavila negativan izveštaj.[3]
Reference
uredi- ↑ Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S. (2002). „Pharmacology of flibanserin”. CNS Drug Rev. 8 (2): 117-142. DOI:10.1111/j.1527-3458.2002.tb00219.x. PMID 12177684.
- ↑ Jolly E, Clayton A, Thorp J, Lewis-D’Agostino D, Wunderlich G, Lesko L (April 2008). „Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)”. Sexologies 17 (Suppl 1): S133–4. DOI:10.1016/S1158-1360(08)72886-X.
- ↑ Spiegel online: Pharmakonzern stoppt Lustpille für die Frau, 8 October 2010 (in German)
Povezano
urediSpoljašnje veze
uredi
- Vijagra za žene?
- Marazziti D, Palego L, Giromella A, et al. (June 2002). „Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain”. Int. J. Neuropsychopharmacol. 5 (2): 131-40. DOI:10.1017/S1461145702002869. PMID 12135537.
- Podhorna J, Brown RE (June 2000). „Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety”. Br J Pharmacol 130 (4): 739-746. DOI:10.1038/sj.bjp.0703364. PMC 1572126. PMID 10864879. Arhivirano iz originala na datum 2013-01-06. Pristupljeno 2014-04-05.
- Brambilla A, Baschirotto A, Grippa N, Borsini F (December 1999). „Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain”. Eur Neuropsychopharmacol 10 (1): 63-7. DOI:10.1016/S0924-977X(99)00056-5. PMID 10647099.